Eutilex Co. Ltd. has entered a strategic partnership with Zhejiang Huahai Pharmaceutical Ltd., both based in China, to accelerate Eutilex’s antibody and anti-tumor T cell therapy development programs.   Under the agreement, Huahai will take a $30 million equity stake in Eutilex and in return will receive an exclusive license to develop and commercialize EU-101, an antibody developed for cancer treatment.   Eutilex is eligible to receive milestone payments from Huahai for EU-101 approve...